Biocept, Inc. (BIOC)

NASDAQ: BIOC · IEX Real-Time Price · USD
2.16
-0.16 (-6.90%)
At close: May 26, 2023, 4:00 PM
2.22
+0.06 (2.78%)
After-hours: May 26, 2023, 7:59 PM EDT
-6.9%
Market Cap 1.28M
Revenue (ttm) 11.38M
Net Income (ttm) -32.23M
Shares Out 592.91K
EPS (ttm) -56.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 318,522
Open 2.15
Previous Close 2.32
Day's Range 2.05 - 2.39
52-Week Range 2.05 - 47.70
Beta 0.92
Analysts n/a
Price Target n/a
Earnings Date May 10, 2023

About BIOC

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSC... [Read more]

Sector Healthcare
IPO Date Feb 5, 2014
Employees 50
Stock Exchange NASDAQ
Ticker Symbol BIOC
Full Company Profile

Financial Performance

In 2022, Biocept's revenue was $25.86 million, a decrease of -57.78% compared to the previous year's $61.25 million. Losses were -$32.09 million, 1036.2% more than in 2021.

Financial Statements

News

Biocept Announces Pricing of $5.0 Million Underwritten Public Offering

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten...

5 days ago - Business Wire

Biocept Announces One-for-Thirty Reverse Stock Split

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that ...

1 week ago - Business Wire

Biocept Reports First Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 ...

2 weeks ago - Business Wire

Biocept Reports 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 ...

1 month ago - Business Wire

Enrollment Begins in FORESEE Clinical Trial Using Biocept's CNSide™ to Evaluate Patients with Leptomeningeal Metastases

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical tr...

2 months ago - Business Wire

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purc...

3 months ago - Business Wire

Biocept to Explore Strategic Alternatives and Implement Restructuring Plan

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has en...

5 months ago - Business Wire

Biocept Reports Third Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended Sept...

6 months ago - Business Wire

Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Dir...

6 months ago - Business Wire

Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investiga...

6 months ago - Business Wire

Biocept Reports Second Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June ...

7 months ago - Business Wire

Biocept to Present at the LD Micro Main Event XV

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV...

7 months ago - Business Wire

Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patien...

8 months ago - Business Wire

Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held today, October 14 at 1 p.m...

8 months ago - Business Wire

Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held October 14 at 1 p.m. Easte...

8 months ago - Business Wire

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “Notice”) on August 17, 202...

10 months ago - Business Wire

Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its Quarterly Report on Form 10-...

10 months ago - Business Wire

Biocept Appoints RSM as Independent Auditor

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP (“RSM”) as it...

1 year ago - Business Wire

Biocept to Hold Business Strategy Conference Call Today

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized busi...

1 year ago - Business Wire

Biocept Reports First Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 ...

1 year ago - Business Wire

Biocept Reports 2021 Fourth Quarter and Full Year Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December...

1 year ago - Business Wire

Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and...

1 year ago - Business Wire

Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022

SAN DIEGO--(BUSINESS WIRE)---- $BIOC--Biocept to report 2021 fourth quarter and full year financial results on March 30, 2022.

1 year ago - Business Wire

Biocept Appoints Philippe Marchand as Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--Biocept names Philippe Marchand as new Chief Operating Officer to oversee strategic business operations, including its CNSide CSF assay.

1 year ago - Business Wire

Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer

SAN DIEGO--(BUSINESS WIRE)--Biocept highlights CNSide assay's ability to aid clinical research efforts to improve treatment of metastatic cancers involving brain.

1 year ago - Business Wire